Celularity Case Studies

# BIOVANCE®

## Removal of failed hardware with excisional tissue transfer closure

**DONALD E. MRDJENOVICH, DPM, CWS, FACCWS – ALTOONA, PA**

*"Use of BIOVANCE implant in a high-risk surgical incision reduced the extent of incision dehiscence. Tissue was viable with minimal scarring."*

### Patient Background

**Female | Age: 75**

Type 2 diabetes mellitus (DM) with polyneuropathy, hypertension (HTN), rheumatoid arthritis (RA), hypothyroidism, congestive heart failure (CHF), acid reflux, coronary artery disease (CAD)

### PRESENTATION

| | |
|---|---|
| **Background:** | Diabetic neuropathic chronic foot ulcer greater than 1 year |
| **Initial treatment:** | Medial 1st metatarsal LT foot |
| **Findings:** | Did not show findings of granulation and necrotic tissue |
| **Pre-op x-rays:** | • Antibiotic ointment<br>• Autolytic and sharp debridement |




Ulcer pre-op

### TREATMENT STRATEGY

- Procedure:
  - Removal of failed hardware
  - Remove scar tissue around ulcer site
- BIOVANCE allograft membrane at each level during layered closure (capsule, subcutaneous/subcuticular)
- Offload with surgical shoe




Day 12 post-op

## POST-OP

- Decreased local incision/wound inflammation
- At day 33 (Figure 1) – immature epithelial migration (immature closure), stable base
- At day 47 (Figure 2) – full closure and minimal scarring
- Patient returned to extra-depth shoe within 6 weeks with continued stability at incision site
- No complications with viable tissue and minimal scarring

### Additional comments

- Use of BIOVANCE implant in high-risk surgical incision reduced extent of incision dehiscence
- No major safety concerns were observed



**Figure 1.** Ulcer post-op day 33. Magnified at 250%



**Figure 2.** Ulcer post-op day 47. Magnified at 250%

(BIOVANCE Safety Information)

**INDICATIONS FOR USE**

BIOVANCE is an allograft intended for use as a biological membrane covering that provides the extracellular matrix while supporting the repair of damaged tissue. As a barrier membrane, BIOVANCE is intended to protect the underlying tissue and preserve tissue plane boundaries with minimized adhesion or fibrotic scarring. Indications include, but are not limited to, surgical covering, wrap or barrier, application to partial- and full-thickness, acute and chronic wounds (such as, traumatic and complex wounds, burns, surgical and Mohs surgery sites; and diabetic, venous, arterial, pressure and other ulcers), including wounds with exposed tendon, muscle, bone or other vital structures.

**CONTRAINDICATIONS, WARNINGS, AND PRECAUTIONS**

BIOVANCE is contraindicated in patients with a known hyper-sensitivity to BIOVANCE. If a patient has an adverse reaction related to the use of BIOVANCE, immediately discontinue its use. BIOVANCE should not be used on clinically infected wounds.

The pouch contents are sterile if the pouch is unopened and undamaged. Do not use if package seal is broken. Discard material if mishandling has caused possible damage or contamination. Do not resterilize.

BIOVANCE must be used prior to the expiration date on the product pouch. BIOVANCE should not be used together with a collagenase product on the wound.

**Please refer to the BIOVANCE Package Insert for complete product information.**

**For product information, product complaints, or adverse reaction reporting, call 1-844-963-2273.**

For more information, please contact Celularity at 1-844-963-2273 or visit www.biovance.net

celularity